Exact Mass: 741.6059624
Exact Mass Matches: 741.6059624
Found 500 metabolites which its exact mass value is equals to given mass value 741.6059624,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(16:1(9Z)/P-18:1(11Z))
C42H80NO7P (741.5672099999999)
PC(16:1(9Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/P-18:1(11Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(16:1(9Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/P-18:1(11Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(16:1(9Z)/P-18:1(9Z))
C42H80NO7P (741.5672099999999)
PC(16:1(9Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/P-18:1(9Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(18:2(9Z,12Z)/P-16:0)
C42H80NO7P (741.5672099999999)
PC(18:2(9Z,12Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/P-16:0), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-16:0/18:2)
PC(P-16:0/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(11Z)/16:1(9Z))
C42H80NO7P (741.5672099999999)
PC(P-18:1(11Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/16:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of palmitoleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(11Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/16:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of palmitoleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(9Z)/16:1(9Z))
C42H80NO7P (741.5672099999999)
PC(P-18:1(9Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/16:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of palmitoleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(9Z)/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/16:1(9Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of palmitoleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(O-16:1(9Z)/18:2(9Z,12Z))
C42H80NO7P (741.5672099999999)
PC(O-16:1(9Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-16:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of Palmitoleyl alcohol at the C-1 position and one chain of linoleic acid at the C-2 position. The Palmitoleyl alcohol moiety is derived from whale oil, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-16:1(9Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-16:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of Palmitoleyl alcohol at the C-1 position and one chain of linoleic acid at the C-2 position. The Palmitoleyl alcohol moiety is derived from whale oil, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
Curcumene-alpha
C42H80NO7P (741.5672099999999)
Cyanidin 3,5-O-diglucoside
C42H80NO7P (741.5672099999999)
1-O-beta-D-Galactopyranosyl-N-(2R-hydroxy-15-methylpalmitoyl)-17-methylsphinga-4E,8E-dienin
(2R)-N-{(1S,2R,3E,7E)-1-[(beta-D-glucopyranosyloxy)methyl]-2-hydroxy-8-methylhexadeca-3,7-dien-1-yl}-2-hydroxyoctadecanamide
GlcCer(d14:1(4E)/22:1(13Z)(2OH))
GlcCer(d14:2(4E,6E)/22:0(2OH))
GlcCer(d16:2(4E,6E)/20:0(2OH))
PC(O-16:0/18:3)
C42H80NO7P (741.5672099999999)
PC(O-16:0/18:3)[S]
C42H80NO7P (741.5672099999999)
Lecithin
C42H80NO7P (741.5672099999999)
PE(P-20:0/17:2(9Z,12Z))
C42H80NO7P (741.5672099999999)
PC O-34:3
C42H80NO7P (741.5672099999999)
PE O-37:3
C42H80NO7P (741.5672099999999)
(R)-N-[(1S,2R,3E,7Z)-1-[(beta-D-Glucopyranosyloxy)methyl]-2-hydroxy-3,7-heptadecadienyl]-2-hydroxyoctadecanamide
beta-D-galactosyl-N-(nonadecanoyl)sphingosine
A D-galactosyl-N-acylsphingosine where the ceramide N-acyl group is nonadecanoyl.
N-icosanoyl-1-O-beta-D-glucosyl-15-methylhexadecasphing-4-enine
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (Z)-nonadec-9-enoate
C42H80NO7P (741.5672099999999)
[2-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]oxy-3-octoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C42H80NO7P (741.5672099999999)
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide
(11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octatriaconta-11,14,17,20,23,26,29,32,35-nonaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]dotriaconta-8,11,14,17,20,23,26,29-octaenamide
2-(3-Octanoyloxy-2-pentacosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]tetratriaconta-10,13,16,19,22,25,28,31-octaenamide
(12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexatriaconta-12,15,18,21,24,27,30,33-octaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexatriaconta-9,12,15,18,21,24,27,30,33-nonaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-(1,3-dihydroxyoctan-2-yl)dotetraconta-9,12,15,18,21,24,27,30,33,36,39-undecaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-N-[(4E,8E,12E)-1,3-dihydroxyicosa-4,8,12-trien-2-yl]triaconta-6,9,12,15,18,21,24,27-octaenamide
(12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]dotetraconta-12,15,18,21,24,27,30,33,36,39-decaenamide
2-(3-Nonanoyloxy-2-tetracosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(2-Icosanoyloxy-3-tridecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(2-Nonadecanoyloxy-3-tetradecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(2-Docosanoyloxy-3-undecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(2-Heptadecanoyloxy-3-hexadecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(3-Decanoyloxy-2-tricosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(2-Octadecanoyloxy-3-pentadecanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-(3-Dodecanoyloxy-2-henicosanoyloxypropoxy)-2-[2-(trimethylazaniumyl)ethoxy]acetate
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octatriaconta-8,11,14,17,20,23,26,29,32,35-decaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-(1,3-dihydroxydecan-2-yl)tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]tetraconta-10,13,16,19,22,25,28,31,34,37-decaenamide
(E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]octadec-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]henicos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]nonadecane-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxyicosanoylamino)tricosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]icos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]pentacos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] (14Z,17Z,20Z)-octacosa-14,17,20-trienoate
C42H80NO7P (741.5672099999999)
(4E,8E)-3-hydroxy-2-(2-hydroxyheptadecanoylamino)hexacosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]heptadec-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxynonadecanoylamino)tetracosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)heptadeca-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]docos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)octadeca-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]tricosane-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]nonadec-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]henicosane-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]tricos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxyoctadecanoylamino)pentacosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]pentacosane-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxyhenicosanoylamino)docosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]tetracos-4-ene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxytricosanoylamino)icosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]heptadecane-1-sulfonic acid
C43H83NO6S (741.5940777999999)
(4E,8E)-3-hydroxy-2-(2-hydroxydocosanoylamino)henicosa-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]propan-2-yl] nonanoate
C42H80NO7P (741.5672099999999)
(4E,8E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)nonadeca-4,8-diene-1-sulfonic acid
C43H83NO6S (741.5940777999999)
[2-hexanoyloxy-3-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C42H80NO7P (741.5672099999999)
[3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]-2-octanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C42H80NO7P (741.5672099999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C42H80NO7P (741.5672099999999)
2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxyoctadecane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (Z)-heptadec-9-enoate
C42H80NO7P (741.5672099999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (12Z,15Z,18Z)-hexacosa-12,15,18-trienoate
C42H80NO7P (741.5672099999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
C42H80NO7P (741.5672099999999)
3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]pentacosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]icosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-2-(henicosanoylamino)-3-hydroxytricos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(icosanoylamino)tetracos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(nonadecanoylamino)pentacos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-2-(hexacosanoylamino)-3-hydroxyoctadec-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(pentacosanoylamino)nonadec-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-2-(docosanoylamino)-3-hydroxydocos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(tetracosanoylamino)icos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]tetracosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(octadecanoylamino)hexacos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
2-[[(Z)-docos-13-enoyl]amino]-3-hydroxydocosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxytricosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
(E)-3-hydroxy-2-(tricosanoylamino)henicos-4-ene-1-sulfonic acid
C44H87NO5S (741.6304611999999)
3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]hexacosane-1-sulfonic acid
C44H87NO5S (741.6304611999999)
2-[4-(3-henicosanoyloxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]acetic acid
2-[4-[12-hydroxy-3-[(Z)-icos-11-enoyl]oxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracosan-2-yl]tridec-8-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadecan-2-yl]docos-11-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosan-2-yl]hexadec-7-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosan-2-yl]dodec-5-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradecan-2-yl]tricos-11-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadecan-2-yl]henicos-9-enamide
(Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadecan-2-yl]octadec-11-enamide
N-(heptadecanoyl)-1-beta-glucosyl-4E-eicosasphingenine
N-(hexadecanoyl)-1-beta-glucosyl-4E-heneicosasphingenine
N-(pentadecanoyl)-1-beta-glucosyl-4E-docosasphingenine
(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadecan-2-yl]icos-11-enamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]nonadecanamide
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-8-en-2-yl]tricosanamide
(E)-N-[(2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosan-2-yl]hexadec-9-enamide
(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadecan-2-yl]octadec-9-enamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-8-en-2-yl]henicosanamide
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
(E)-N-[(2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosan-2-yl]heptadec-9-enamide
2-[[(2S,3R,4E,8E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2S,3R,4E,8E)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2S,3R,4E,6E)-2-[[(E)-docos-13-enoyl]amino]-3-hydroxypentadeca-4,6-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-8-en-2-yl]heptadecanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]tricosanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]docosanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-8-en-2-yl]docosanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-4-en-2-yl]icosanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-8-en-2-yl]nonadecanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicos-8-en-2-yl]hexadecanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-8-en-2-yl]icosanamide
N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocos-8-en-2-yl]pentadecanamide
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]nonadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-4-en-2-yl]henicosanamide
2-[[(2S,3R,4E,8E)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-8-en-2-yl]octadecanamide
[(E,2S,3R)-3-hydroxy-2-[[(E)-tetracos-15-enoyl]amino]nonadec-4-enyl] dihydrogen phosphate
C43H84NO6P (741.6035933999999)
[(E,2S,3R)-2-[[(E)-hexacos-17-enoyl]amino]-3-hydroxyheptadec-4-enyl] dihydrogen phosphate
C43H84NO6P (741.6035933999999)
(E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadecan-2-yl]docos-13-enamide
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tricos-11-enoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(docosanoylamino)-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonadecanoylamino)octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(hexadecanoylamino)-3-hydroxyhenicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octadecanoylamino)nonadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxypentacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tricosanoylamino)tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tetradecanoylamino)tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(icosanoylamino)heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(henicosanoylamino)-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentadecanoylamino)docosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)tetracosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxypentacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]docosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(heptadecanoylamino)-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]tetracosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyhenicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(butanoylamino)-3-hydroxytritriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(octanoylamino)nonacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(17Z,20Z)-octacosa-17,20-dienoyl]amino]non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]nonoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(propanoylamino)tetratriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(pentanoylamino)dotriaconta-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-acetamido-3-hydroxypentatriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]heptadecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(nonanoylamino)octacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)hexacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(decanoylamino)-3-hydroxyheptacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxypentadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(hexanoylamino)-3-hydroxyhentriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]tridecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]tridec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E,12E)-2-(heptanoylamino)-3-hydroxytriaconta-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetracosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
Hex1Cer(36:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(37:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved